Although a clinical trial of intratumoral injection of TLR9 ligand (CMP-001) along with nivolumab for resectable melanoma has been conducted (NCT03618641), to the best of our knowledge, published data are only available for neoadjuvant immunotherapy using only CPIs55. Here, TLR9 is linked to melanoma.